- Home
- LSF vs SERA Comparison
LSF vs SERA Comparison
Compare LSF & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSF
- SERA
- Stock Information
- Founded
- LSF 2015
- SERA 2008
- Country
- LSF United States
- SERA United States
- Employees
- LSF N/A
- SERA N/A
- Industry
- LSF Packaged Foods
- SERA Precision Instruments
- Sector
- LSF Consumer Staples
- SERA Health Care
- Exchange
- LSF Nasdaq
- SERA Nasdaq
- Market Cap
- LSF 65.5M
- SERA 70.4M
- IPO Year
- LSF 2020
- SERA 2021
- Fundamental
- Price
- LSF $6.35
- SERA $2.49
- Analyst Decision
- LSF Strong Buy
- SERA
- Analyst Count
- LSF 2
- SERA 0
- Target Price
- LSF $12.00
- SERA N/A
- AVG Volume (30 Days)
- LSF 26.2K
- SERA 803.1K
- Earning Date
- LSF 08-06-2025
- SERA 08-06-2025
- Dividend Yield
- LSF N/A
- SERA N/A
- EPS Growth
- LSF N/A
- SERA N/A
- EPS
- LSF N/A
- SERA N/A
- Revenue
- LSF $45,040,358.00
- SERA $115,000.00
- Revenue This Year
- LSF $23.40
- SERA $390.13
- Revenue Next Year
- LSF $20.11
- SERA $440.54
- P/E Ratio
- LSF N/A
- SERA N/A
- Revenue Growth
- LSF 25.04
- SERA N/A
- 52 Week Low
- LSF $3.40
- SERA $1.37
- 52 Week High
- LSF $10.90
- SERA $9.13
- Technical
- Relative Strength Index (RSI)
- LSF 48.20
- SERA 53.89
- Support Level
- LSF $6.03
- SERA $1.82
- Resistance Level
- LSF $6.74
- SERA $4.09
- Average True Range (ATR)
- LSF 0.37
- SERA 0.36
- MACD
- LSF 0.01
- SERA 0.10
- Stochastic Oscillator
- LSF 53.33
- SERA 35.74
About LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.